Overview

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
A phase I, randomized, open-label and active-control study to assess the PK, PD and safety profiles of LY01005 versus goserelin comparator to be conducted in the USA.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Treatments:
Goserelin